Lee’s Pharma to Initiate P-III Trial of Socazolimab as 1L Treatment of Extensive-stage Small-Cell Lung Cancer

 Lee’s Pharma to Initiate P-III Trial of Socazolimab as 1L Treatment of Extensive-stage Small-Cell Lung Cancer

Lee’s Pharma to Initiate P-III Trial of Socazolimab as 1L Treatment of Extensive-stage Small-Cell Lung Cancer

Shots:

  • The NMPA has approved Lee pharma to initiate P-III clinical trials to evaluate Socazolimab + CT as a 1L treatment of ES-SCLC. The study is expected to initiate patient recruitment in Q2’21
  • The clearance is based on the results from P- Ib trial in which Socazolimab + carboplatin and etoposide demonstrated a promising efficacy & safety profile in patients with ES- SCLC
  • Socazolimab is a fully human anti-PD-L1 mAb, licensed from Sorrento to COF for the greater China territory. Earlier, Socazolimab has received NMPA’s BTD in Feb’2021 for recurrent or metastatic cervical cancer while Lee intends to file the NDA for the same indication in Q2’21

Click here ­to­ read full press release/ article | Ref: Sorrento | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post